Fri, Aug 22, 2014, 12:27 PM EDT - U.S. Markets close in 3 hrs 33 mins


% | $
Quotes you view appear here for quick access.

Cliffs Natural Resources Inc. Message Board

data_analyst_dude 7 posts  |  Last Activity: Aug 7, 2014 5:24 PM Member since: Feb 1, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • data_analyst_dude by data_analyst_dude Aug 7, 2014 5:24 PM Flag

    doesn't mean anything just saying.

  • data_analyst_dude data_analyst_dude Jul 13, 2014 1:22 AM Flag

    I doubled down as well at $3.41. Let's do this. My average is $4.12

  • data_analyst_dude by data_analyst_dude Jul 10, 2014 11:35 AM Flag

    What is going on? Down everyday!

  • data_analyst_dude by data_analyst_dude Jun 27, 2014 7:48 PM Flag

    Sant Chawla M.D. Director of the Sarcoma Oncology Center and Principal Investigator of the Phase III pivotol trial is very excited about it's ENORMOUS potential. Ever see the movie Armageddon? It's like a space ship landing on an asteroid (tumor) carrying a nuclear war head to blow it to hell.

  • The Overall Survival(OS) data from the Phase IIb first-line trail will be shared sometime in the second half of 2014. Well, that means you better be in this stock starting July 1st. It can come out any day from Tuesday until the end of December.

    "We are hopeful that the next stage of development for aldoxorubicin, a well-tolerated single agent that lacks the cardiotoxicity associated with doxorubicin therapy, will demonstrate its potential to meaningfully extend survival, and will lead to a new treatment option for patients fighting this aggressive, life-threatening cancer."

    A total of 123 patients with advanced soft tissue sarcomas were enrolled in the 31-centre Phase IIb trial and they were randomised 2:1 to receive either 350mg/m2 of aldoxorubicin or 75mg/m2 of doxorubicin every three weeks for up to six cycles.

    These patients were then followed every six weeks with CT scans to monitor tumour size.

    Two approaches were used to evaluate the efficacy of aldoxorubicin compared with doxorubicin in these patients, which include evaluation by the study investigators, as well as assessment by a blinded central laboratory review.

    The trial's primary endpoint was PFS and secondary endpoints included PFS at six months for each group, ORR and overall survival, which will be reported when the clinical trial is complete.

    CytRx president and chief executive officer Steven Kriegsman said these results were selected for presentation at the 2014 American Society for Clinical Oncology (ASCO) Annual Meeting.

    "We look forward to discussing the data with the oncology community and to reporting the full overall survival results from this trial in the second half of 2014," Kriegsman said.

    "In parallel, we continue to actively enroll patients in our pivotal global Phase III trial in second-line STS. In that Phase III clinical trial, we are permitted to dose until progression, which could substantially enhance the benefit for sarcoma patients."

  • data_analyst_dude by data_analyst_dude Jun 8, 2014 11:22 PM Flag

    Citi credit analyst James Finnerty initiated coverage on KB Home (NYSE: KBH) 4.75% 2019s with a Buy rating.

    Finnerty said, "We believe KBH has upwards ratings momentum in the medium term given company guidance for improved profitability in 2014 which is expected to lead to the reversal of a large percentage of their Deferred Tax Allowance (DTA). We believe the resulting benefit to balance sheet leverage could be a potential positive rating catalyst."

    He added, "KBH management is guiding for full year of profitability in 2014 which they expect will allow them to reverse a significant portion of their DTA of $844mm. The reversal would boost shareholders equity and therefore reduce debt/cap. At recent investor day guided to Net Debt/Cap ratio target of 40-50% by 2016 vs. 77% as of 1Q14 (57% adjusted for DTA reversal). At the time they also noted that ratings agencies were waiting for the reversal before incorporating the lower leverage into KBH’s ratings.

  • Reply to

    20 Million shares short

    by blueiz1020 Jun 5, 2014 2:50 PM
    data_analyst_dude data_analyst_dude Jun 5, 2014 5:15 PM Flag

    The tide will will change and the shorts are sensing it. Not buying their negativity! Holding KBH long!

15.86-0.35(-2.16%)12:27 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.